摘要【目的】 探讨多西他赛联合卡培他滨、奥沙利铂对中晚期胃癌患者血清肿瘤标志物水平的影响。【方法】60例中晚期胃癌患者,按照化疗方案分为A组(亚叶酸钙+5-氟尿嘧啶+奥沙利铂, n =28)与B组(多西他赛+卡培他滨+奥沙利铂,DOX化疗方案, n =32),比较两组化疗效果,两组治疗前、后血清肿瘤标志物糖类抗原125(CA125)、癌胚抗原(CEA)、组织多肽特异性抗原(TPS)、CA199、细胞角蛋白19可溶性片段(CYFRA21-1)和血清白介素-2(IL-2)、肿瘤坏死因子-α(TNF-α)、血管内皮生长因子(VEGF)、一氧化氮(NO)水平的变化,统计化疗毒副反应。【结果】①B组总缓解率略高于A组,但差异无显著性( P >0.05);②化疗前两组CA125、CEA、TPS、CYFRA21-1、CA199、IL-2、TNF-α、VEGF、NO水平比较差异无显著性( P >0.05),化疗后两组上述各指标均降低( P <0.05),B组化疗后肿瘤标志物水平均低于A组( P <0.05);③B组毒副反应发生率略低于A组,但差异无显著性( P >0.05)。【结论】DOX化疗方案治疗中晚期胃癌患者临床总缓解率高,耐受性好,同时可降低其血清肿瘤标志物水平及炎症因子、血管内皮因子水平。
Abstract：【Objective】To investigate the effect of docetaxel combined with capecitabine and oxaliplatin on serum levels of tumor markers in patients with advanced gastric cancer. 【Methods】Sixty patients with advanced gastric cancer were analyzed retrospectively. According to different chemotherapy regimens, the patients were divided into FOLFOX group (group A ,calcium folinate +5- fluorouracil + oxaliplatin, n=28) and group DOX (group B,docetaxel + capecitabine + oxaliplatin, n =32). The effects of chemotherapy were compared between the two groups, and changes of serum levels of tumor markers carbohydrate CA125, CEA,TPS,CA199, CYFRA21-1 in the two groups before and after treatment were monitored. The changes of serum levels of IL-2, TNF-α, VEGF and NO were compared between the two groups before and after treatment. 【Results】①The total remission rate of the group B was slightly higher than that of the group A ( P > 0.05). ②Before chemotherapy, there were no statistically significant differences between the two groups in levels of CA125, CEA, TPS, CYFRA21-1, CA199, IL-2, TNF-α, VEGF and NO ( P > 0.05), after treatment, the above indexes were decreased in the two groups ( P < 0.05), and the levels of tumor markers in the group B were lower than those in the group A ( P < 0.05). ③The incidence of side effects in the group B was slightly lower than that in the group A ( P > 0.05). 【Conclusion】The total remission rate of patients with advanced gastric cancer treated by DOX chemotherapy is high and the tolerance of patients is good. Meanwhile, the regimen can decrease the levels of serum tumor markers, inflammation and vascular endothelial factors.
张怒, 王静, 陈真林, 杨勇. 多西他赛联合卡培他滨、奥沙利铂对中晚期胃癌患者血清肿瘤标志物水平的影响[J]. 医学临床研究, 2018, 35(7): 1286-1288.
ZHANG Nu, WANG Jing, CHEN Zhen-lin, et al. Effect of Docetaxel Combined with Capecitabine and Oxaliplatin on Serum Levels of Tumor Markers in Patients with Advanced Gastric Cancer. JOURNAL OF CLINICAL RESEARCH, 2018, 35(7): 1286-1288.
2018, Vol. 35 
